Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it is supporting a satellite symposium hosted by The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), entitled: ‘Navigating cancer anorexia-cachexia: the modified Glasgow Prognostic Score in the spotlight’, at the 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting
Lugano, Switzerland, December 5, 2017 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it is supporting a satellite symposium hosted by The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), entitled: ‘Navigating cancer anorexia-cachexia: the modified Glasgow Prognostic Score in the spotlight’, at the 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting.
This educational event hosted by SCWD will focus on and explain diagnostic methods and the practical solutions to cancer cachexia. The audience will be made up of oncologists, cardiologists, gerontologists, palliative care specialists, primary care physicians and nurses, the groups that on a day to day basis have to treat these debilitating conditions associated with cancer.
This symposium brings together a panel of world-renowned experts in cachexia, sarcopenia, and muscle wasting. The event will be chaired by Maurizio Muscaritoli, MD, Director of the Clinical Nutrition Management Unit, Sapienza University of Rome, Rome, Italy and the panel members comprises Donald McMillan, PhD, Professor of Surgical Science, University of Glasgow, Glasgow, UK and Barry Laird, MD, Senior Clinical Lecturer in Palliative Medicine, University of Edinburgh, Edinburgh, UK.
The symposium will be held on Friday, 8th December 2017 at 13:15 – 14:15 in the Sheraton Roma Hotel & Conference Centre, Rome, Italy. Below the programme:
- Switching on the navigation system: welcome and introduction: By Professor Maurizio Muscaritoli (Italy)
- Blazing the trial: cancer anorexia-cachexia identification using the modified Glasgow Prognostic Score: By Professor Donald McMillan (UK)
- Plotting the course: modified Glasgow Prognostic Score subgroup analysis in the ROMANA trials and beyond: By Dr Barry Laird (UK)
- The road ahead: summary and close of meeting: By Professor Maurizio Muscaritoli (Italy)
Silvia Sebastiani, Head of Medical Affairs, commented: “Helsinn remains committed to cancer patients’ quality of life and general well-being and we are delighted to be supporting this educational event. We support the work of The Society on Sarcopenia, Cachexia and Wasting Disorders and look forward to hearing from and working with leading experts on how to improve diagnosis and treatment methods for these debilitating conditions, as we continue to strive to improve the lives of patients living with cancer worldwide.”
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
For more information:
Helsinn Group Media Contact:
Group Head of Communication
Tel: +41 (0) 91 985 21 21